Vimarsana
Biggest News Aggregation in the World

Page 4 - Multiple Sclerosis Centers News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Multiple Sclerosis Centers. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Multiple Sclerosis Centers Today - Breaking & Trending Today

Relapsing MS patients fared better after switch to Kesimpta | Multiple Sclerosis News Today - Vimarsana News

Relapsing MS patients fared better after switch to Kesimpta | Multiple Sclerosis News Today

People with relapsing MS who experienced disease activity while on oral therapies had less disease activity after switching to Kesimpta.

Multiple Changes in NMOSD Treatment Tied to Poorer Outcomes - Vimarsana News

Multiple Changes in NMOSD Treatment Tied to Poorer Outcomes

Multiple treatment transitions in patients with NMOSD are associated with increased neurological harm, including increased relapse risk and disease progression.

Analysis of protein levels in blood helps ID MS patient subgroups | Such groupings may help improve individualized treatment: Study - Vimarsana News

Analysis of protein levels in blood helps ID MS patient subgroups | Such groupings may help improve individualized treatment: Study

Analyses of protein levels in the blood can be used to identify groups of MS patients with distinct clinical features, which may improve care.

Long-Term Freedom From NMOSD Relapse With Satralizumab - Vimarsana News

Long-Term Freedom From NMOSD Relapse With Satralizumab

The use of the monoclonal antibody satralizumab for the long-term treatment of neuromyelitis optica spectrum disorder provides sustained freedom from relapse with no new safety concerns over 5 years.

Briumvi approved in Europe for active, relapsing forms of MS | Multiple Sclerosis News Today - Vimarsana News

Briumvi approved in Europe for active, relapsing forms of MS | Multiple Sclerosis News Today

The European Commission has approved Briumvi to treat people with relapsing forms of MS who have active disease.